Inhibrx Biosciences, Inc. (INBX)

Inhibrx Biosciences Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	-155.09	1,688	-241.36	-115.33	-
Depreciation & Amortization	2.61	2.29	1.19	1.23	-
Other Amortization	1.8	2.07	4.9	-	-
Loss (Gain) From Sale of Assets	0	0.01	0	0.02	-
Loss (Gain) on Equity Investments	-	-	1.63	-	-
Stock-Based Compensation	11.38	58.52	24.85	17.79	-
Other Operating Activities	1.8	-1,997	0.13	1.62	-
Change in Accounts Receivable	0.73	0.38	-0.54	0.13	-
Change in Accounts Payable	-5.59	17.9	2.11	-0.38	-
Change in Unearned Revenue	-	-	-0.17	-1.1	-
Change in Other Net Operating Assets	-1.03	33.77	13.94	5.21	-
Operating Cash Flow	-143.39	-194.41	-193.31	-90.81	-
Capital Expenditures	-0.05	-2.6	-4.59	-0.69	-
Investing Cash Flow	-0.04	-2.6	-4.59	-0.69	-
Issuance of Common Stock	0.35	71.68	202.32	-	-
Other Financing Activities	-0.13	-	-0.36	91.5	-
Financing Cash Flow	100.19	71.68	201.96	91.5	-
Net Cash Flow	-43.24	-125.33	4.06	-	-
Free Cash Flow	-143.44	-197.01	-197.9	-91.5	-
Free Cash Flow Margin	-10245.64%	-98503.00%	-10994.56%	-6957.95%	-
Free Cash Flow Per Share	-9.27	-13.15	-16.80	-2.28	-
Cash Interest Paid	6.39	11.51	26.72	-	-
Cash Income Tax Paid	0	0	0	0	-
Levered Free Cash Flow	-117.6	-118.26	-106.38	-55.74	-
Unlevered Free Cash Flow	-113.76	-111.89	-91.38	-55.74	-
Change in Working Capital	-5.9	52.05	15.35	3.86	-

Updated Nov 14, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q